Wednesday, February 13, 2013

AMD Genes Don't Predict Response to Lucentis or Avastin

“New findings from a landmark clinical trial show that although certain gene variants may predict whether a person is likely to develop age-related macular degeneration (AMD), a potentially blinding eye disease that afflicts more than nine million Americans, these genes do not predict how patients will respond to Lucentis and Avastin, the two medications most widely used to treat the 'wet' form of AMD,” says Science Daily. “This new data from the Comparison of AMD Treatment Trials (CATT), published online in Ophthalmology, the journal of the American Academy of Ophthalmology, found no significant association between four gene variants and outcomes that measured the patients' responses to treatment.” Read more.

No comments:

Post a Comment

Post a Comment